drugset / Trial / NCT02799680
Allogeneic CART-33 for Relapsed/Refractory CD33+ AML
Phase 1
Unknown
12 enrolled
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Chinese PLA General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 33 (CD33)-directed chimeric antigen receptor modified T cells (CART-33) infusions in patients with relapsed / refractory acute myeloid leukemia (AML).
Timeline
- Start
- 2015-10
- Primary completion
- 2017-05
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART33 | Cell therapy | — | — |